Muscular Dystrophy Canada, Canadian Neuromuscular Disease Registry, NMD4C partner to ensure Canadians can access Facioscapulohumeral muscular dystrophy (FSHD) cure(s)

Published: 05 March 2023

Muscular Dystrophy Canada and the Canadian Neuromuscular Disease Registry are working together with NMD4C  to introduce a patient registry and collect information to build a Canada-wide core dataset for Facioscapulohumeral muscular dystrophy.

Learn more about this project at: https://muscle.ca/2023/02/27/mdc-cndr-nmd4c-partner-to-ensure-canadians-can-access-fshd-cures/.

text reading Canadian FSHD registry, with icons in centre of page and CNDR and MDC logos underneath.

Read next...

Text reading: Cataloguing NMD Basic Research Expertise in Canada, image of researcher pipetting on the right.

NMD4C to Develop a List of Canadian Neuromuscular Research Labs to Support Research Collaborations and Training

We are excited to launch an initiative from the NMD4C cell and animal-based NMD research tasks to develop a centralized list of Canadian neuromuscular research labs, and we need your help to collect this information!

MDC and NMD4C now recruiting: clinical trials and community of practice manager

MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager

Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!

2024 NMD4C early-career awards now accepting applications

Annual NMD4C Early-Career Awards Program Accepting Applications

We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!

NMD4C pre-clinical science team seeking trainee input. Let us know if you'd like to be involved in an advisory committee.

NMD4C Pre-clinical Science Pillar Seeking Trainee Input

The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you! 

Dr Natasha Chang and Dr Rashmi Kothary receive MDC Dr David Green Awards in 2023.

NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards

We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.